Prognostic tissue markers in melanoma | Zendy

Moore David A | Zendy; Pringle J Howard | Zendy; Saldanha Gerald S | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Prognostic tissue markers in melanoma

Author(s) -

Moore David A,

Pringle J Howard,

Saldanha Gerald S

Publication year - 2012

Publication title -

histopathology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.626

H-Index - 124

eISSN - 1365-2559

pISSN - 0309-0167

DOI - 10.1111/j.1365-2559.2011.03910.x

Subject(s) - melanoma , biomarker , biomarker discovery , medicine , diagnostic biomarker , polymerase chain reaction , pathology , molecular biomarkers , oncology , biology , cancer , gene , cancer research , proteomics , genetics

Moore D A, Pringle J H & Saldanha G S  (2012) Histopathology 60, 679–689  Prognostic tissue markers in melanoma Prognosis for patients diagnosed with cutaneous melanoma is currently based upon histopathological features alone, although tumours which are morphologically similar can behave differently. Numerous putative biomarkers have been identified in an attempt to aid prognostication for primary melanoma, using methods which include immunhistochemistry, polymerase chain reaction (PCR), array comparative genomic hybridization (CGH) and gene expression arrays. Despite this wide body of research, no biomarkers for prognosis in melanoma have been translated or are close to translation into clinical practice. In this review selected prognostic biomarkers are evaluated and the factors influencing successful biomarker translation, including phases of biomarker development and study design, are explored in an attempt to highlight the current gap between prognostic melanoma biomarker research and clinical translation.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research